We can be in the cliffs of the pivotal moment in Alzheimer’s disease study. In the clinical trial data published this week, scientists presented their initial evidence that they could delay the symptoms of people of destiny at all for the development of Alzheimer’s at a young age.
Researchers at Washington University School of Medicine led the study with the goal of testing whether the experimental anti -amyloid drug called Gantenerumab could help people with Alzheimers in the form of inherited. In the lower set of the longest patients, the drug showed to reduce the risk of symptoms by 50%. The result is a follow -up, but external experts are carefully optimistic about what it means in the future of Alzheimer’s treatment.
“The result [Alzheimer’s] At the preclinical stage of pathology, pathology can be effective in slowing or preventing disease development. ”Thomas M. Wisnightski, director of cognitive neurology center of NYU LANGONE HEALTH, said to Gizmodo.
Gantenerumab It is one of the many similar drugs developed by scientists for Alzheimer’s. It is an antibody made in a laboratory that targets beta amyloids, and one of the two proteins is considered to play an important role in causing Alzheimer’s (the other is a tau). For people with Alzheimer, an incorrectly folded version of amyloid beta is stacked in the brain, forming a hard mass known as plaques, and eventually receives organs. Scientists said that with drugs such as Gantenerumab, which prevents these plaque formation, the Alzheimer’s stop or at least slow down.
Unfortunately, it did not burn this hypothesis smoothly. Many anti -amyloid drugs have initially showed their promises and have failed only in a larger test that have already been tested for those who have already experienced Alzheimer’s symptoms. The list includes Gantenerumab. In late 2022, pharmaceutical company Roche End development The failure of the drug after a pair of III test.
But more recent anti-amyloid drugs have proven to have a moderate but noticeable effect on slowing down the speed of Alzheimer’s, which is enough to obtain the approval of the food pharmacy. Some researchers, including Washu Medicine, hoped to be more effective when anti -amyloid treatment was administered a long time before Alzheimer’s symptoms appeared.
Since 2012, researchers and others have begun to prevent anti-amyloid preparations for the dominantly inherited Alzheimer’s anti-amyloid preparations. Most of these tests were not successful in using Gantenerumab.
Originally, when the Gantenerumab study ended in 2020, researchers found that they reduced people’s amyloid levels. However, it is too early to know whether most patients will not be sick for 10 to 15 years at the start of the study. The researchers then decided to openly provide Gantenerumab to patients (including placebo or patients taking other drugs) as part of expansion research.
This is the latest result of this study. Post People were excited at Lancet Neurology on Wednesday.
“Everyone in this study was destined to develop Alzheimer’s disease, and some of them were yet.” name In college. “We don’t know how long they will take without symptoms.
In other words, there is an important warning in the study.
First of all, the result only suggests potential preventive interests, WisnieWski pointed out. The drug could reduce the risk of cognitive decrease in the larger groups of those who do not have symptoms, but this decrease was not statistically significant (perhaps the total number of patients was 73, perhaps 73, Wisn needski said. However, the sub -set included only 22 patients, which seemed to reduce the possibility of reduction by 50%.
The test also ended earlier than expected by many patients due to Roche’s abandonment, and some dropped out for other reasons. The drug is generally safe and withstanding, but Arias, an abnormal 3rd amyloid -related video, a marker of swelling or bleeding of the brain, has developed. Arias is a known side effect of these drugs, but most episodes are inconspicuous by the patient. The two patients experienced severe aria, which led researchers to stop treatment. During the study, no life -threatening events or deaths have been reported.
In general, this study is not a decisive evidence that anti-amyloid drugs can work much in advance against Alzheimer’s. However, since this form is essentially inevitable, these results are suggested that it can be treated for the first time in clinical trials. With the initial approval of the Lecanemab and Donanemab for the classic version of neurotroductive disorders, there seems to be something real.
“We already know that anti-amyloid antibodies (AAAs) can slow down the progress of the common sporadic Alzheimer’s in Lecca Nemab and Donamab data.” This paper focuses on proving similar phenomena in Alzheimer’s early on genes using other AAAs.
Gandy, WisniesWski and researchers all agree that this is only the beginning. Early onset and Classic Alzheimer’sIncluding the dominant inherited Alzheimer’s network test device, including several things operated by Washu. This test is testing a newly approved new experimental anti -amyloid drug that can show much more protection than Gantenerumab. Researchers were also able to convert many patients to Levanemab in their original expansion studies, but the data at this stage must still be analyzed.
It is initially, but there may be true hope for this untreated disease on the horizon.
